

WAHT-KD-019

Treatment of Inflammatory Bowel Disease with Biologics (in patients over 15 years of age)

Tuberculosis Assessment and Exclusion Guidelines

| | | |
|---|---|----------------|
| Key Document code: | Treatment of Inflammatory Bowel Disease with Biologics (In patients over 15 years of age) | |
| Key Document Owner: | Helen Osinski | Senior IBD CNS |
| Approved by: | Medicines Safety committee | |
| Date of Approval: | 04 th November 2019 | |
| This is the most upto date and should be used until a revised version is in place: | 4 th November 2021 | |

Key Amendments

| Date | Amendment | Approved by |
|-------------|------------------|--------------------|
| | | |

In patients receiving a Biologic there is an increased risk of clinical tuberculosis (TB) developing or latent disease being reactivated.

- Patients should be screened for active or latent TB infection **before** receiving a Biologic. This should be through the completion of a detailed patient history to determine previous TB or recent contact with the disease before the **first** infusion, in conjunction with T-Spot blood test.
- If the T-Spot is equivocal it should be repeated, if it remains equivocal or is positive advice should be sought from the Respiratory physicians.
- Any patient with active TB will generally require 6 months of chemotherapy with minimum of 2 months full chemotherapy before consideration of Biologic therapy.
- In patients with previous TB, if past treatment is considered to have been adequate by respiratory consultant they may start Biologic treatment but will require careful monitoring with chest x-ray every 3 months and sputum cultures if respiratory symptoms develop.
- Patients of Black African ethnicity aged over 15 years and **all** patients born in the Indian Sub-continent should be considered for chemoprophylaxis with isoniazid for 6 months.
- For inpatients requiring rescue Infliximab the T-Spot should still be taken. However if it is deemed imperative to start the Infliximab and the patient agrees after adequate counselling (as to the possible consequences if the T-Spot then turns out to be positive) the infusion can be given.

References:

Rampton, D.S. (2005) Preventing TB in patients with Crohn's disease needing Infliximab or other anti-TNF therapy. **GUT**. 54:1360-1362.

British Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF- α treatment. **Thorax** 60:800-805

Please note that the key documents are not designed to be printed, but to be used on-line. This is to ensure that the correct and most up-to-date version is being used. If, in exceptional circumstances, you need to print a copy, please note that the information will only be valid for 24 hours and should be read in conjunction with the key document supporting information page

WAHT-KD-019

Treatment of Inflammatory Bowel Disease with Biologics (in patients over 15 years of age)

NICE guideline (2016) Tuberculosis NG33. <https://www.nice.org.uk/guidance/ng33>

Please note that the key documents are not designed to be printed, but to be used on-line. This is to ensure that the correct and most up-to-date version is being used. If, in exceptional circumstances, you need to print a copy, please note that the information will only be valid for 24 hours and should be read in conjunction with the key document supporting information page